The Food Safety and Drug Administration (FSDA) of Uttar Pradesh has dismantled a widespread organized syndicate involved in circulating counterfeit medicines through fraudulent billing, cross-billing, and paper transactions across the state. In its latest high-profile legal action, the enforcement agency registered its sixth First Information Report (FIR) as part of an aggressive statewide campaign aimed at purging spurious pharmaceuticals from the legitimate supply chain. The crackdown has exposed a sophisticated network of wholesale distributors, dummy firms, illegal warehouses, and clandestine manufacturing facilities spanning Uttar Pradesh, Uttarakhand, and Rajasthan.
Authorities confirmed that the fraudulent operation enabled racketeers to inject spurious allopathic medicines, physician samples, and expired drugs worth crores of rupees into retail markets and medical stores. The enforcement drive has led to the sealing of multiple pharmaceutical establishments in key trading hubs such as Lucknow and Agra, alongside the immediate suspension of wholesale trading licenses.
Unearthing the Modus Operandi: Paper Transactions and Cross-Billing
The investigation revealed an intricate web of deceptive financial practices designed to cloak the origins of counterfeit drugs and lend them an aura of legitimacy. According to FSDA officials, the syndicate relied on fake invoicing and cross-billing among a cluster of interconnected pharmaceutical entities, including Mishra Associates, Mishra Medical Agency, Shri Ashok Pharmaceuticals, Bharat Pharma, and MDH Pharma. These entities generated massive paper sales to one another without executing actual physical shipments of medicines or conducting genuine bank-to-bank monetary transfers.
Physical verifications conducted by enforcement officers at several registered premises revealed no actual medicine stock, despite corporate ledgers indicating heavy volume purchases. Further inquiries exposed the use of proxy proprietors to shield the true masterminds. Registered owners of certain front firms gave written statements alleging that key operator Devendra Shukla managed the businesses without their knowledge or consent, keeping them completely unaware of the multi-crore billing transactions carried out under their names.
Suspicious Pricing and Counterfeit Augmentin Supply Chain
A critical breakthrough occurred when FSDA inspectors detected glaring price anomalies during routine scrutiny of financial registers and procurement invoices. Investigators discovered that firms such as Mishra Medical Agency and Mishra Associates were recording wholesale purchases of popular antibiotics, including Augmentin Duo 625, at a rate of ₹56.60 per strip. This price was dramatically below the legitimate manufacturer landing cost of ₹116.70 per strip, immediately raising red flags regarding product authenticity and illicit sourcing.
Subsequent raids and laboratory testing confirmed that the heavily discounted drugs circulating through the network were counterfeit, posing severe health hazards to unsuspecting patients suffering from acute bacterial infections. The illicit network also engaged in repackaging expired medications and illegally procuring government hospital supplies reserved strictly for public health schemes, diverting them into commercial retail channels for massive profit margins.
Inter-State Network, Raids, and Regulatory Enforcement
The footprint of the counterfeit drug syndicate extends well beyond Uttar Pradesh. Acting on disclosures obtained during interrogations and document analysis, multi-agency teams conducted coordinated raids on an illicit pharmaceutical manufacturing unit operating out of Dehradun, Uttarakhand. The facility was found illegally producing counterfeit variants of leading brand-name allopathic drugs. Enforcement agencies booked four key operators associated with the Dehradun plant, while simultaneously initiating legal proceedings against suppliers and logistics operators based in Rajasthan who facilitated the transport of contraband consignments.
In Uttar Pradesh, the FSDA sealed nine major wholesale pharmaceutical establishments in Lucknow’s Aminabad market and eight illegal warehouses in Agra, seizing spurious drug stocks worth over ₹3.6 crore. Cases have been registered at police stations under stringent provisions of the Bharatiya Nyaya Sanhita (BNS) for cheating, forgery, and criminal conspiracy, alongside relevant sections of the Drugs and Cosmetics Act. The Commissioner of the UP FSDA has directed drug inspectors across all districts to maintain heightened surveillance, initiate swift license cancellation proceedings against non-compliant firms, and dismantle all remaining nodes of the inter-state network.
